Literature DB >> 16849474

Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice.

Sabine Oertelt1, Zhe-Xiong Lian, Chun-Mei Cheng, Ya-Hui Chuang, Kerstien A Padgett, Xiao-Song He, William M Ridgway, Aftab A Ansari, Ross L Coppel, Ming O Li, Richard A Flavell, Mitchell Kronenberg, Ian R Mackay, M Eric Gershwin.   

Abstract

Primary biliary cirrhosis (PBC) is an autoimmune disease of the liver, characterized by lymphocytic infiltrates in portal tracts, selective destruction of biliary epithelial cells, and anti-mitochondrial Abs (AMAs). The elucidation of early events in the induction of tissue inflammation and autoimmunity in PBC has been hampered by the cryptic onset of the disease, the practical limitations in accessing the target tissue, and the lack of a suitable animal model. We demonstrate in this study that a mouse transgenic for directed expression of a dominant-negative form of TGF-beta receptor type II (dnTGFbetaRII), under the direction of the CD4 promoter, mimics several key phenotypic features of human PBC, including spontaneous production of AMAs directed to the same mitochondrial autoantigens, namely PDC-E2, BCOADC-E2, and OGDC-E2. The murine AMAs also inhibit PDC-E2 activity. Moreover, there is lymphocytic liver infiltration with periportal inflammation analogous to the histological profile in human PBC. Additionally, the serum cytokine profile of affected mice mimics data in human PBC. The concomitant presence of these immunopathological features in the transgenic mice suggests that the TGF-betaRII pathway is implicated in the pathogenesis of PBC. Finally, these data point away from initiation of autoimmunity by mechanisms such as molecular mimicry and more toward activation of an intrinsically self-reactive T cell repertoire in which necessary regulatory T cell influences are lacking.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849474     DOI: 10.4049/jimmunol.177.3.1655

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  122 in total

1.  Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies.

Authors:  Allyson K Martínez; Luca Maroni; Marco Marzioni; Syed T Ahmed; Mena Milad; Debolina Ray; Gianfranco Alpini; Shannon S Glaser
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

2.  B cell depletion therapy exacerbates murine primary biliary cirrhosis.

Authors:  Amy Dhirapong; Ana Lleo; Guo-Xiang Yang; Koichi Tsuneyama; Robert Dunn; Marilyn Kehry; Thomas A Packard; John C Cambier; Fu-Tong Liu; Keith Lindor; Ross L Coppel; Aftab A Ansari; M Eric Gershwin
Journal:  Hepatology       Date:  2010-12-28       Impact factor: 17.425

Review 3.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

Review 4.  Role of autoimmunity in primary biliary cirrhosis.

Authors:  Tian-Yan Shi; Feng-Chun Zhang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 5.  A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis.

Authors:  Patrick S C Leung; Jinjung Choi; Guoxiang Yang; Elena Woo; Thomas P Kenny; M Eric Gershwin
Journal:  Expert Rev Mol Diagn       Date:  2016-03-30       Impact factor: 5.225

6.  Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells.

Authors:  Wenting Huang; Kritika Kachapati; David Adams; Yuehong Wu; Patrick S C Leung; Guo-Xiang Yang; Weici Zhang; Aftab A Ansari; Richard A Flavell; M Eric Gershwin; William M Ridgway
Journal:  J Autoimmun       Date:  2014-02-18       Impact factor: 7.094

Review 7.  Animal models of primary biliary cirrhosis.

Authors:  Ya-Hui Chuang; William M Ridgway; Yoshiyuki Ueno; M Eric Gershwin
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

Review 8.  The genetics of complex cholestatic disorders.

Authors:  Gideon M Hirschfield; Roger W Chapman; Tom H Karlsen; Frank Lammert; Konstantinos N Lazaridis; Andrew L Mason
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

9.  Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease.

Authors:  Kanji Wakabayashi; Zhe-Xiong Lian; Patrick S C Leung; Yuki Moritoki; Koichi Tsuneyama; Mark J Kurth; Kit S Lam; Katsunori Yoshida; Guo-Xiang Yang; Toshifumi Hibi; Aftab A Ansari; William M Ridgway; Ross L Coppel; Ian R Mackay; M Eric Gershwin
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

10.  CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis.

Authors:  Shinji Shimoda; Kenichi Harada; Hiroaki Niiro; Akinobu Taketomi; Yoshihiko Maehara; Koichi Tsuneyama; Kentaro Kikuchi; Yasuni Nakanuma; Ian R Mackay; M Eric Gershwin; Koichi Akashi
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.